CLINICAL STUDY ON AT-2266
スポンサーリンク
概要
- 論文の詳細を見る
AT-2266, a newly developed pyridonecarboxylic acid derivative, was administered to 7 patients with respiratory tract infections and 2 patients with urinary tract infections. The dosage was 600 to 900 mg/ day given in divided doses three times daily for 5 to 14 days. The clinical response was excellent in 1 case, good in 6 cases, and fair in 2 cases. The success rate was 77.8%.<BR>Neither side effects nor abnormal laboratory findings were found.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.